NewAmsterdam Pharma (NASDAQ:NAMS) Issues Earnings Results

NewAmsterdam Pharma (NASDAQ:NAMS) posted its quarterly earnings data on Wednesday. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23), FiscalAI reports. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.

NewAmsterdam Pharma Trading Down 3.3%

Shares of NewAmsterdam Pharma stock traded down $1.18 on Thursday, reaching $34.58. 556,816 shares of the company were exchanged, compared to its average volume of 679,159. The stock has a fifty day moving average price of $34.03 and a 200-day moving average price of $32.43. The firm has a market capitalization of $3.92 billion, a price-to-earnings ratio of -16.87 and a beta of 0.06. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $42.00.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Guggenheim upped their price objective on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday. Stifel Nicolaus upped their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Leerink Partners restated an “outperform” rating and set a $55.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. Royal Bank Of Canada increased their price target on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Finally, The Goldman Sachs Group increased their price target on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a report on Tuesday, December 2nd. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $47.00.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $33.25, for a total transaction of $199,500.00. Following the transaction, the insider directly owned 73,481 shares in the company, valued at $2,443,243.25. This trade represents a 7.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Louise Frederika Kooij sold 32,612 shares of the business’s stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $31.80, for a total transaction of $1,037,061.60. Following the transaction, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $774,425.40. This represents a 57.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 298,647 shares of company stock valued at $10,236,050. 20.84% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN grew its stake in shares of NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after buying an additional 300 shares in the last quarter. Empowered Funds LLC acquired a new stake in NewAmsterdam Pharma during the 4th quarter valued at $85,000. Persistent Asset Partners Ltd bought a new position in NewAmsterdam Pharma during the fourth quarter worth $138,000. Guggenheim Capital LLC acquired a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at $224,000. Finally, Orion Porfolio Solutions LLC acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth about $230,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.